INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
Dec 11, 2023 |
Director, Bd. Co-Chair, President & CSO
|
Director, Bd. Co-Chair, President & CSO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 12,841 | $844.09 | 752,486 |
Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 130,714 | $483.25 | 750,224 |
Mar 09, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | $30.63 | 713,990 |
Dec 15, 2016 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,079 | $20.32 | 697,000 |
Dec 03, 2009 |
Director, EVP CSO & Pres Regn Res Labs
|
Director, EVP CSO & Pres Regn Res Labs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 100,000 | $8.77 | 688,235 |
Dec 15, 2016 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 10,429 | $380.09 | 686,571 |
Oct 30, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 182,818 | $11.64 | 682,818 |
Dec 13, 2017 |
Director, President & CSO
|
Director, President & CSO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 95,050 | $385.08 | 680,612 |
Oct 30, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 3,806 | $559.08 | 679,012 |
Dec 03, 2009 |
Director, EVP CSO & Pres Regn Res Labs
|
Director, EVP CSO & Pres Regn Res Labs | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 45,463 | $19.29 | 642,772 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.